N-Caffeoyldopamine
N-Caffeoyldopamine (Compound 6i) is an amyloid-beta aggregation inhibitor. N-Caffeoyldopamine can inhibit Aβ aggregation to form nano-rod-like structures, thereby preventing β-sheet formation. N-Caffeoyldopamine can be used for Alzheimer's disease research[1].
Product Specifications
UNSPSC
12352005
Target
Amyloid-β
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/aβ-in-9.html
Purity
90.00
Smiles
OC1=C(O)C=CC(CCNC(/C=C/C2=CC(O)=C(O)C=C2)=O)=C1
Molecular Formula
C17H17NO5
Molecular Weight
315.32
References & Citations
[1]Xu F, et al. Synthesis and evaluation of catecholamine derivatives as amyloid-beta aggregation inhibitors. Bioorg Med Chem Lett. 2024 Jul 15;107:129788.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![MDMX (MDM4) Mouse Monoclonal Antibody [Clone ID: LBI4B5]](https://cdn.genprice.uk/genprice/uk/genprice4.webp)
MBS6000430-01 0.1 mg
ACP6 (Lysophosphatidic Acid Phosphatase Type 6, Acid Phosphatase 6, Lysophosphatidic, Acid Phosphatase-like Protein 1, PACPL1, ACPL1, LPAP, UNQ205/PRO231)
Ask
View Details 
MBS6000430-02 5x 0.1 mg
ACP6 (Lysophosphatidic Acid Phosphatase Type 6, Acid Phosphatase 6, Lysophosphatidic, Acid Phosphatase-like Protein 1, PACPL1, ACPL1, LPAP, UNQ205/PRO231)
Ask
View Details